Physician profile
Brandon Vu
NPI 1609452663
$1,709.35
in general payments reported to CMS, 2019-2025
27 companies · $1,594 in 2025
The $1,594 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $73.52 · 2024: $42.31 · 2025: $1,594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,639 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,639.36 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $182.39 | 2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $179.22 | 2025 | |
| Harmony Biosciences LLC | $114.55 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $110.28 | 2025 | |
| Glaxosmithkline, LLC. | $99.29 | 2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $91.13 | 2025 | Breztri, Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $90.35 | 2025 | |
| Exact Sciences Corporation | $88.71 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Collegium Pharmaceutical, INC. | $86.22 | 2024-2025 | Belbuca |
| Corcept Therapeutics | $80.30 | 2025 | Korlym |
| Lilly USA, LLC | $78.69 | 2025 | Mounjaro, Zepbound |
| Medtronic, INC. | $73.52 | 2023 | Signia |
| Sumitomo Pharma America, INC. | $65.28 | 2025 | Gemtesa |
| Incyte Corporation | $44.71 | 2025 | Niktimvo, Jakafi, Zynyz |
| Axsome Therapeutics, INC. | $37.33 | 2025 | Symbravo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $36.60 | 2025 | |
| Azurity Pharmaceuticals, INC. | $35.00 | 2024-2025 | Horizant |
| Amgen INC. | $32.45 | 2025 | Otezla, Repatha |
| Astellas Pharma US INC | $32.19 | 2025 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $30.20 | 2025 | Caplyta |
| Averitas Pharma INC. | $21.50 | 2025 | Qutenza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.28 | 2025 | Jardiance |
| Exeltis, USA INC. | $19.11 | 2025 | Slynd |
| Lundbeck LLC | $16.82 | 2025 | Rexulti |
| Protega Pharmaceutials INC | $16.00 | 2025 | Roxybond |
| Xeris Pharmaceuticals, INC. | $14.73 | 2025 | Gvoke Hypopen |
| Esperion Therapeutics, INC. | $13.50 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Vu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.